皮病药物试验结果显示, 奥鲁卡治疗公司的股价上了20%. Oruka Therapeutics shares surge 20% on psoriasis drug trial results.

周一,Oruka Therapeutics股票升,因为该公司报告了其牛皮药ORKA-001的二期a试验结果呈阳性. Oruka Therapeutics stock surged Monday after the company reported positive interim Phase 2a trial results for its psoriasis drug ORKA-001. 数据显示,63. 5% 的患者在第16周内实现了完全的皮肤清除,治疗表明安全性较好. The data showed 63.5% of patients achieved complete skin clearance by Week 16, with the treatment demonstrating a favorable safety profile. 由于其强大效果和每年一次的剂量可能增加投资者的信心,导致股票在高交易量下幅超过20%. The strong efficacy and potential for once-yearly dosing drove investor confidence, causing the shares to rise more than 20% on high trading volume.